MeSH term | MeSH ID | Detail |
---|---|---|
Lung Neoplasms | D008175 | 171 associated lipids |
Body Weight | D001835 | 333 associated lipids |
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with clarithromycin
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Kunin M et al. | Mycobacterium chelonae peritonitis in peritoneal dialysis. Literature review. | 2014 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:24569948 |
Fan Y et al. | High and low doses of clarithromycin treatment are associated with different clinical efficacies and immunomodulatory properties in chronic rhinosinusitis. | 2014 | J Laryngol Otol | pmid:24555753 |
Hanson KE et al. | Rapid molecular detection of inducible macrolide resistance in Mycobacterium chelonae and M. abscessus strains: a replacement for 14-day susceptibility testing? | 2014 | J. Clin. Microbiol. | pmid:24554745 |
Markert C et al. | Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers. | 2014 | Br J Clin Pharmacol | pmid:23738582 |
Khoshnood A et al. | Replacement of clarithromycin with azithromycin in triple therapy regimens for the eradication of Helicobacter pylori: A randomized clinical trial. | 2014 | J Med Life | pmid:25408735 |
Noh TK et al. | Infection with Mycobacterium fortuitum during acupoint embedding therapy. | 2014 | J. Am. Acad. Dermatol. | pmid:24831334 |
Fowler J and Mahlen SD | Localized cutaneous infections in immunocompetent individuals due to rapidly growing mycobacteria. | 2014 | Arch. Pathol. Lab. Med. | pmid:25076301 |
Ueda Y et al. | [Obstructive pneumonia and brain abscess due to Nocardia elegans in a patient with systemic lupus erythematosus]. | 2014 | Kansenshogaku Zasshi | pmid:24974451 |
NegrÃn-González J et al. | Psychiatric adverse reaction induced by clarithromycin. | 2014 | Eur Ann Allergy Clin Immunol | pmid:24853570 |
Kurosaki Y et al. | [Two cases of pulmonary Mycobacterium avium complex disease with resistance to clarithromycin]. | 2014 | Kekkaku | pmid:24979948 |
Tümgör G et al. | Comparison of standard and standard plus vitamin E therapy for Helicobacter pylori eradications in children. | 2014 | Turk J Gastroenterol | pmid:25910378 |
Çiftci İH et al. | Comparison of FISH, RFLP and agar dilution methods for testing clarithromycin resistance of Helicobacter pylori. | 2014 | Turk J Gastroenterol | pmid:25910373 |
Lee JY et al. | Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance. | 2014 | Dig. Dis. Sci. | pmid:24599773 |
Zhao HM et al. | [Clinical effect of triple therapy combined with Saccharomyces boulardii in the treatment of Helicobacter pylori infection in children]. | 2014 | Zhongguo Dang Dai Er Ke Za Zhi | pmid:24661511 |
Ohe M and Hashino S | Successful treatment of primary immune thrombocytopenia in aged patients using clarithromycin. | 2014 | J. Formos. Med. Assoc. | pmid:24630039 |
Zhou L et al. | A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. | 2014 | Am. J. Gastroenterol. | pmid:24642580 |
Heo J and Jeon SW | [Changes in the eradication rate of conventional triple therapy for Helicobacter pylori infection in Korea]. | 2014 | Korean J Gastroenterol | pmid:24651586 |
Kang BK et al. | [New therapeutic strategies against Helicobacter pylori]. | 2014 | Korean J Gastroenterol | pmid:24651587 |
Lee JY and Kim N | [Future trends of Helicobacter pylori eradication therapy in Korea]. | 2014 | Korean J Gastroenterol | pmid:24651589 |
Patsche CB et al. | Disseminated Mycobacterium celatum disease with prolonged pulmonary involvement. | 2014 | Int. J. Infect. Dis. | pmid:25008771 |
Jesus FP et al. | In vitro synergism observed with azithromycin, clarithromycin, minocycline, or tigecycline in association with antifungal agents against Pythium insidiosum. | 2014 | Antimicrob. Agents Chemother. | pmid:25001300 |
Ke AB et al. | Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies. | 2014 | Clin. Pharmacol. Ther. | pmid:24747234 |
Ghosh N et al. | Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma. | 2014 | Am. J. Hematol. | pmid:24723438 |
Mendu ML and Waikar SS | Drug-drug interactions and acute kidney injury: caveat prescriptor. | 2014 | Am. J. Kidney Dis. | pmid:24820318 |
Gisbert JP et al. | Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection. | 2014 | Dig. Dis. Sci. | pmid:24126798 |
Kuroda H et al. | [Three cases of lenalidomide-resistant IgA myeloma for which a response was regained after the addition of clarithromycin]. | 2014 | Gan To Kagaku Ryoho | pmid:25248908 |
Farley R et al. | Antibiotics for bronchiolitis in children under two years of age. | 2014 | Cochrane Database Syst Rev | pmid:25300167 |
Iwanczak B et al. | Genotypic and clinical differences of seropositive Helicobacter pylori children and adults in the Polish population. | 2014 | J. Physiol. Pharmacol. | pmid:25554984 |
Rakici H et al. | Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy. | 2014 | Digestion | pmid:25547786 |
Karamanolis GP et al. | The evolution of Helicobacter pylori antibiotics resistance over 10 years in Greece. | 2014 | Digestion | pmid:25531953 |
Hemphill A et al. | Treatment of echinococcosis: albendazole and mebendazole--what else? | 2014 | Parasite | pmid:25526545 |
Kawai T et al. | Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group). | 2014 | J. Gastroenterol. Hepatol. | pmid:25521730 |
Wang B et al. | Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. | 2014 | World J. Gastroenterol. | pmid:25356059 |
Morakul B et al. | Dissolution enhancement and in vitro performance of clarithromycin nanocrystals produced by precipitation-lyophilization-homogenization method. | 2014 | Eur J Pharm Biopharm | pmid:25201298 |
Parekh TM et al. | Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas. | 2014 | JAMA Intern Med | pmid:25179404 |
Kutluk G et al. | Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains? | 2014 | Eur J Gastroenterol Hepatol | pmid:25171023 |
Higashi F et al. | Additional treatment with clarithromycin reduces fever duration in patients with influenza. | 2014 | Respir Investig | pmid:25169846 |
Teh X et al. | Functional and molecular surveillance of Helicobacter pylori antibiotic resistance in Kuala Lumpur. | 2014 | PLoS ONE | pmid:25003707 |
Lyons J et al. | An unusual lung mass post stem cell transplantation. | 2014 | Transpl Infect Dis | pmid:24995624 |
Lee JW et al. | A comparison between 15-day sequential, 10-day sequential and proton pump inhibitor-based triple therapy for Helicobacter pylori infection in Korea. | 2014 | Scand. J. Gastroenterol. | pmid:24988873 |
Wang Y et al. | Efficacy and safety of ecabet sodium as an adjuvant therapy for Helicobacter pylori eradication: a systematic review and meta-analysis. | 2014 | Helicobacter | pmid:24826809 |
Graham DY et al. | Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. | 2014 | Clin. Gastroenterol. Hepatol. | pmid:23751282 |
Pan-In P et al. | Ethyl cellulose nanoparticles: clarithomycin encapsulation and eradication of H. pylori. | 2014 | Carbohydr Polym | pmid:24815396 |
Ichihara A et al. | Case of disseminated cutaneous Mycobacterium chelonae infection mimicking cutaneous vasculitis. | 2014 | J. Dermatol. | pmid:24801916 |
Togami K et al. | Involvement of intestinal permeability in the oral absorption of clarithromycin and telithromycin. | 2014 | Biopharm Drug Dispos | pmid:24801141 |
Bernut A et al. | In vivo assessment of drug efficacy against Mycobacterium abscessus using the embryonic zebrafish test system. | 2014 | Antimicrob. Agents Chemother. | pmid:24798271 |
Adebisi AO and Conway BR | Lectin-conjugated microspheres for eradication of Helicobacter pylori infection and interaction with mucus. | 2014 | Int J Pharm | pmid:24792977 |
Bolhuis MS et al. | In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis. | 2014 | Eur. Respir. J. | pmid:24791826 |
Mark TM et al. | Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma. | 2014 | Leuk. Lymphoma | pmid:24576165 |
Takazono T et al. | Paradoxical response to disseminated non-tuberculosis mycobacteriosis treatment in a patient receiving tumor necrosis factor-α inhibitor: a case report. | 2014 | BMC Infect. Dis. | pmid:24576098 |